Relmada Therapeutics, Inc. RLMD
Set alert
3.58 USD +0.14 +4.07%
At close · Oct 30
3.50 -0.08 -2.23%
After hours · Oct 30, 4:13 PM ET
3.31 Day range 3.66
2.20 52-week range 7.86
- YTD
- -25.88%
- 1 year
- +54.31%
- Open
- 3.42
- Prev close
- 3.44
- Mkt cap
- 381.88M
- Vol
- 1.41M
- Avg vol
- 1.33M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.31
- High
- 3.66
- Forward P/E
- -0.19
- Beta
- 0.41
- Short ratio
- 4.52
- Inst. own
- 46.06%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.53
- 200-d avg
- 3.33
- 1y target
- 0.86667
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 4 weeks ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 11, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| RSI: Oversold | Sep 9, 2026 | 1 month ago |
| RSI: Oversold | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| RSI: Oversold | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 11.45M
- Enterprise value
- 27.93M
- Trailing P/E
- 0.00
- Forward P/E
- -0.19
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.13
- EPS (TTM)
- -2.86
- Beta
- 0.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -18.51M
- Total cash
- 70.44M
- Total debt
- 0
- Return on equity
- -100.41%
- Shares outstanding
- 30.17M
- Short % of float
- 4.23%
- 50-day average
- 2.53
- 200-day average
- 3.33
Analyst view
Consensus: none
Price target (mean) 0.86667 -75.8% downside
Now 3.58
- Target (low)
- 0.60
- Target (mean)
- 0.86667
- Target (high)
- 1.00
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RLMD Revenue — quarterly 0
RLMD Net income — quarterly -12.91M
RLMD EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.65 | -0.72 | -0.07 | -10.77% |
| Aug 7, 2024 | Jun 1, 2024 | -0.83 | -0.59 | +0.24 | +28.92% |
| May 8, 2024 | Mar 1, 2024 | -0.90 | -0.72 | +0.18 | +20.00% |
| Mar 19, 2024 | Dec 1, 2023 | -0.88 | -0.84 | +0.04 | +4.55% |
| Nov 8, 2023 | Sep 1, 2023 | -0.95 | -0.73 | +0.22 | +23.16% |
| Aug 8, 2023 | Jun 1, 2023 | -0.92 | -0.84 | +0.08 | +8.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Mizuho | down | Outperform | Neutral |
| Dec 4, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Jun 5, 2024 | Goldman Sachs | down | Neutral | Sell |
| Jun 15, 2023 | Mizuho | reit | Buy | Buy |
| Jan 23, 2023 | SVB Leerink | main | — | Outperform |
| Oct 14, 2022 | Goldman Sachs | down | Buy | Neutral |
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- relmada.com
News
- Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call
- Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate
- Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index
- Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
- This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12
- Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session
Your note
Sign in to keep a note on RLMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASAMENTO CHARLES J | Director | Stock Gift | Oct 21, 2024 | 0 |
| ENCE CHARLES | Officer | Purchase | Jan 30, 2024 | 38,970 |
| KELLY PAUL EDWARD | Director | Purchase | Sep 8, 2024 | 212,295 |
| O'GORMAN CEDRIC | Officer | Purchase | May 22, 2023 | 10,121 |
| SHENOUDA MAGED R | Chief Financial Officer | Purchase | Sep 10, 2024 | 88,335 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | Sep 10, 2024 | 384,024 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Resources, Inc. | 13.16% | 1,302,151 | 494.30K | Sep 29, 2024 |
| Vanguard Group Inc | 12.70% | 1,256,705 | 477.05K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 11.99% | 1,186,452 | 450.38K | Sep 29, 2024 |
| Parsons Capital Management, Inc. | 10.13% | 1,002,695 | 380.62K | Sep 29, 2024 |
| Palo Alto Investors Lp | 7.40% | 732,400 | 278.02K | Sep 29, 2024 |
| Deep Track Capital, Lp | 6.82% | 674,833 | 256.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8.61% | 851,916 | 323.39K | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 3.78% | 374,029 | 141.98K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 3.57% | 353,625 | 134.24K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 1.59% | 157,021 | 59.60K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 1.01% | 100,177 | 38.03K | Sep 29, 2024 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.94% | 93,077 | 35.33K | Oct 30, 2024 |